PublizoomAward notice Supplies
Arzneimittelrabattvertrag zu den Arzneimitteln Advate (B02BD02),Recombinate (B02BD02),Rixubis (B02BD04),Feiba (B02BD03),Immunate (B02BD06),Immuseven (B02BD05),Adynovi (B02BD02),Veyvondi (B02BD10)
Notice published in German. The AI analysis summarises it for you in your language.
- Public buyer
- AOK Sachsen - Anhalt
Magdeburg - Place of performance
- Magdeburg
- Amount awarded
- €1 excl. VAT
- Planned end of contract
- 31 August 2028
likely re-tender around March 2028 - Bids received
- 1
- Procedure
- Negotiated procedure without prior publication
The buyer consulted a few companies directly: it is no longer possible to take part. - Publication
- 3 September 2026
- Notice language
- German
AI analysis: go for it or not?
Summary in English, criteria, documents to provide and a GO / NO GO verdict in one minute.
Unlimited analyses during the 14-day Pro trial, no card needed.
Description
Die AOK Sachsen-Anhalt hat zur Behandlung der Hämophilie mit dem Hersteller der Arzneimittel Advate (B02BD02), Recombinate (B02BD02), Rixubis (B02BD04), Feiba (B02BD03), Immunate (B02BD06), Immunine (B02BD04), Immuseven (B02BD05), Adynovi (B02BD02) und Veyvondi (B02BD10) zum 01.09.2026 einen Vertrag gem. § 130a Abs. 8 SGB V i.V.m. § 130c Abs. 1 SGB V abgeschlossen.
Awarded to
CPV codes
European codes that classify what the contract is about. They are how we find the tenders for your trade.
33600000
Winning prices for comparable contracts
- A quarter below
- €1
- Median
- €1
- A quarter above
- €1
Amounts awarded (excl. VAT) over the last 3 years for 73 contracts in the same CPV group (3360…), excluding framework agreements. Half of the contracts fall between the two quartiles. TED source: mostly contracts above the EU thresholds, so amounts tend to be high.
Similar contracts already awarded
Source : TED – Office des publications de l'Union européenne © Union européenne, données retraitées. Reference 607562-2026.